An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)(TERMINATED)
This is a study to evaluate the effectiveness and tolerability of an investigational drug in patients with type 2 diabetes (a specific type of diabetes) who are not currently treated with insulin.
Type 2 Diabetes Mellitus
Drug: MK0478 (muraglitazar)
Drug: Comparator: placebo
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Study to Assess the Efficacy and Tolerability of MK0478 (Muraglitazar, Also, BMS 298585) Coadministered With Insulin in Patients With Type 2 Diabetes|
- The difference in daily dose requirements of insulin after 24 weeks
- (a) HbA1C; (b) FPG; (c) Percent of patients with HbA1C <7.0%; (d) TG, HDL-C, non-HDL-C and apolipoprotein B; (e) Free Fatty Acids (FFA); (f) the incidence of hypoglycemic events at 24 weeks
|Study Start Date:||October 2005|
|Primary Completion Date:||November 2005 (Final data collection date for primary outcome measure)|
The duration of treatment is 30 weeks.